Needham & Company Maintains a 'Buy' on Solta Medical (SLTM); Good Top Line, but Guidance Mildly Disappoints

Needham & Company maintains a 'Buy' on Solta Medical (NASDAQ: SLTM) price target cut $1 to $4.00.

Analyst, Dalton Chandler, said, "It was a good quarter on the top line with a lot of noise between there and EPS. We thought the guidance was mildly
disappointing with revenue growing 20%, but just 6% organically and leading to a small reduction in our estimates. The EPS comes down more dramatically in anticipation of lower margins due to product mix shift."

Needham lowers FY12 EPS estimate from $0.11 to (0.04)

For an analyst ratings summary and ratings history on Solta Medical click here. For more ratings news on Solta Medical click here.

Shares of Solta Medical closed at $3.02 yesterday.

---

Serious News for Serious Traders! Try StreetInsider.com Premium Free!

---

You May Also Be Interested In

• Deutsche Bank Downgrades Workday (WDAY) to Hold
• QBE Insurance Group Ltd. (QBE:AU) (QBEIF) PT Lowered to AUD23.40 at Macquarie
• Johnson Rice Upgrades Magnolia Oil & Gas Corp. (MGY) to Accumulate